Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mutated RAS: Targeting the "Untargetable" with T Cells.

Praveen D Chatani1, James C Yang2

  • 1Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland. Praveen.Chatani@nih.gov.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 13, 2019
PubMed
Summary

Targeting the RAS oncogene family, particularly KRAS, in epithelial cancers is challenging. Modern immunotherapy offers promising new strategies to overcome limitations of existing treatments for these difficult-to-treat cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ASO Visual Abstract: Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience.

Annals of surgical oncology·2026
Same author

Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response.

Journal for immunotherapy of cancer·2026
Same author

Distinct in vivo dynamics of donor-derived stem cell memory CAR T cells post-allogeneic HSCT relapse.

Cell·2026
Same author

Redefining the Lymphadenectomy Standard to Avoid Understaging in Oncologic Colectomies.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Salvage Metastasectomy After Adoptive Cell Transfer for Melanoma: Long-Term Updates.

Annals of surgical oncology·2026
Same author

Liver Metastasectomy to Obtain Tumor-Infiltrating Lymphocytes: Technical Considerations and Report on Single-Center Experience.

Annals of surgical oncology·2026

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • The RAS protein family is crucial in epithelial cancer pathways but has resisted targeted therapies.
  • KRAS mutations are common, driving cancer growth and leading to poor prognoses, making it a key therapeutic target.

Purpose of the Study:

  • To provide a comprehensive review of current strategies for targeting the RAS family, with a focus on KRAS.
  • To highlight advancements in immunotherapy, including adoptive cell therapy, for overcoming KRAS-targeting challenges.

Main Methods:

  • Review of existing literature on small-molecule inhibitors, cancer vaccines, and adoptive cell therapy for RAS-targeted treatment.
  • Analysis of modern immunotherapy techniques to circumvent limitations of conventional drugs and non-specific immune therapies.

Related Experiment Videos

Main Results:

  • Existing targeted therapies have shown limited success against the RAS family.
  • Modern immunotherapy approaches demonstrate significant promise in overcoming previous treatment barriers.

Conclusions:

  • Targeting the RAS oncogene family, especially KRAS, remains a critical unmet need in cancer therapy.
  • Immunotherapy, particularly adoptive cell therapy, presents the most promising avenue for effectively targeting the previously "undruggable" RAS proteins.